ChemMedChem
ChemMedChem
5 years ago

Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of Cancer

Dominik Mumberg, Martina Schäfer, Michael Brands, Carsten Schultz-Fademrecht, Franz von Nussbaum, Kirstin Meyer, Peter Nussbaumer, Philip Lienau, Katja Prelle, Ildiko Terebesi, Rolf Bohlmann, M. Baumann, A. Choidas, Knut Eis, Arne Scholz, Ray Valencia, Hans Briem, Ulrich Lücking, Jan Eickhoff, Karl Ziegelbauer, Gerd Rühter, Ulf Boemer, Dirk Kosemund, Gerhard Siemeister, Bert Klebl, Karsten Denner, Stuart Ince
Selective inhibition of exclusively transcription-regulating PTEFb/CDK9 is a promising new approach in cancer therapy. Starting from lead compound BAY-958, lead optimization efforts strictly focusing on kinase selectivity, physicochemical and DMPK properties finally led to the identification of the orally available clinical candidate atuveciclib (BAY 1143572). Structurally characterized by an unusual benzyl sulfoximine group, BAY 1143572 exhibited the best overall profile in vitro and in vivo, including high efficacy and good tolerability in xenograft models in mice and rats. BAY 1143572 is the first potent and highly selective PTEFb/CDK9 inhibitor that entered clinical trials for the treatment of cancer.

Publisher URL: http://onlinelibrary.wiley.com/resolve/doi

DOI: 10.1002/cmdc.201700447

You might also like
Discover & Discuss Important Research

Keeping up-to-date with research can feel impossible, with papers being published faster than you'll ever be able to read them. That's where Researcher comes in: we're simplifying discovery and making important discussions happen. With over 19,000 sources, including peer-reviewed journals, preprints, blogs, universities, podcasts and Live events across 10 research areas, you'll never miss what's important to you. It's like social media, but better. Oh, and we should mention - it's free.

  • Download from Google Play
  • Download from App Store
  • Download from AppInChina

Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.